Business
Kodiak Sciences Announces Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
PALO ALTO, Calif., March 1, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and
About this update from Kodiak Sciences Inc
[{"type":"text","content":"PALO ALTO, Calif., March 1, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the fourth quarter ended December 31, 2021.\n\"Although our Phase 2b/3 pivotal study in wet AMD did not meet its primary efficacy endpoint, we believe the data served as important validation for KSI-301 and our ABC platform in its ability to extend dosing in a compelling manner for nearly 60% of wet AMD patients and doing so safely, which to our knowledge no other intravitreal anti-VEGF therapy has demonstrated to date,\" said Victor Perlroth, MD, Chief Executive Officer of Kodiak Sciences. \"We do take away important learnings from this initial study, in particular that some patients may benefit from more frequent dosing. The designs of our other ongoing Phase 3 studies have more proactive dosing and therefore we believe less risk of undertreatment. We intend to continue advancing our ongoing pivotal studies of KSI-301 in all of the major retinal vascular disorders for which intravitreal anti-VEGF therapies are currently used, namely our Phase 3 pivotal study BEACON in retinal vein occlusion (\"RVO\"), our paired Phase 3 studies GLEAM/GLIMMER in diabetic macular edema (\"DME\"), our Phase 3 short-interval study DAYLIGHT in wet AMD, and our Phase 3 pivotal study GLOW in non-proliferative diabetic retinopathy without DME (\"NPDR\" without DME). Our BEACON study is expected to have the primary endpoint visit completed in all patients this coming June, with top-line data anticipated to follow shortly thereafter. For our DAYLIGHT study as well as our GLEAM and GLIMMER studies, we expect top-line data in 2023. We remain committed to bringing potentially the longest-interval intravitreal anti-VEGF therapy to patients with retinal vascular diseases and, despite our disappointment in not having met the primary endpoint in our Phase 2b/3 study, I believe we are one step closer to achieving that goal.\"\nRecent Business Highlights\nKSI-301 Phase 2b/3 Pivotal Study in Wet AMD Top-line Data: We recently announced top-line data from our Phase 2b/3 pivotal study of KSI-301 in patients with treatment-naïve wet AMD. The study did not meet its prima...